IP Library Granted Patent US 8,481,676
Granted Patent B2
US 8,481,676 · App. 12/368,219 · Granted Jul 9, 2013

Protein and production process and use thereof

Inventors: Kei Yamana (Tokyo, JP); Yasunori Nakayama (Tokyo, JP); Yoshimasa Takahashi (Tokyo, JP); Eiji Ochiai (Tokyo, JP); Hitoshi Wada (Tokyo, JP); Yoshiaki Azuma (Tokyo, JP)
Assignee: Teijin Pharma Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,676
App. No.
12/368,219
Granted
Jul 9, 2013
Kind
B2
Abstract

[Problems] To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc. [Means for Solving Problems] A novel soluble polypeptide protein.

Claims (10)

1. A soluble polypeptide having an activity of inhibiting angiogenesis and/or an activity of inhibiting bone resorption selected from the group consisting of:

(a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 9;

(b) a polypeptide of (a), which further has a tag sequence added to the N-terminal or C-terminal thereof consisting of about 6 to about 8 consecutive histidine residues;

(c) a polypeptide of (a), which further has a FLAG tag sequence added to the N-terminal or C-terminal thereof;

(d) a polypeptide of (a), which further has tag sequences added to the N-terminal and/or C-terminal thereof consisting of about 6 to about 8 consecutive histidine residues and a FLAG tag sequence;

(e) a polypeptide of (a) to (d), which further has a methionine residue at the N-terminal thereof;

(f) a polypeptide of (a), which further has a glutamine residue at the N-terminal thereof;

(g) a polypeptide of (a), which further has a pyro-glutamine residue at the N-terminal thereof;

(h) a polypeptide of (b) to (d), wherein the amino acid residues added to the N-terminal and/or C-terminal thereof contain modified amino acid residues, which have at least one modified group selected from the group consisting of an acetyl group, formyl group, biotin group, Boc group and Fmoc group.

2. A composition comprising polypeptide of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2014
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 032415/0577 →
Priority Claims (2)
JP 2003-360617 · Oct 21, 2003 · national
JP 2004-143421 · May 13, 2004 · national
Continuity (2)
Continuation 10575626
Related Publication 20090288180A1 · Nov 19, 2009